Mylan (MYL): Cutting PT But EpiPen Drama Is Fully Discounted - Leerink
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Leerink Partners analyst, Jason Gerberry, reiterated his Outperform rating on shares of Mylan (NASDAQ: MYL) but cut his price target to $45.00 from $55.00 after reducing EpiPen estimates. He cut EpiPen sales forecasts by 33-45% (2017-21E) following recent company updates including MYL's planned launch of an authorized generic (AG) later this year.
EpiPen AG will be sold at ~33% lower net price vs. the brand and the analyst believes the threat of a generic is more realistic starting in 2018. His updated forecast calls for out-year (2018E-21E) sales in the $400-725m range, which assumes some value retention through the EpiPen follow-on product. Regarding EpiPen rebates to Medicaid, the analyst believes MYL has complied with the "letter of the law" but investors should factor a future settlement which he sees as preferential to a lingering government probe.
However, the analyst went on to say that he believes cash flows (ex. EpiPen) are sufficient to justify the current price leading him to maintain his Outperform rating.
Shares of Mylan closed at $38.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan's Commitment to Stemming the Tide of HIV/AIDS as Strong as Ever
- UPDATE: Oppenheimer Starts Shopify (SHOP) at Perform
- Jefferies Raises Price Target on Zumiez, Inc. (ZUMZ) to $23 Following 3Q
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!